TIZIANO BARBUI (BERGAMO)
COVID-19 IN MPN
Foundation for Clinical Research, Bergamo Hospital, Italy
The clinical presentation and risk factors for survival in 175 patients with myeloproliferative
neoplasms (MPN) and COVID-19, diagnosed between February and June 2020 are the subject
of this European Leukemia Net (ELN) study, that received the endorsement of the European
Haematology Association (EHA). Here we report the main results in terms of survival and
thrombosis.
After a median follow-up of 50 days, mortality was higher than in the general population and
reached 48% in myelofibrosis (MF). Univariate analysis, showed a significant relationship
between
death and age, male gender, decreased lymphocyte counts, need for respiratory support,
comorbidities and diagnosis of MF while no association with essential thrombocythemia (ET),
polycythemia vera (PV) and prefibrotic-PMF (pre-PMF) was found. In multivariable analysis we
found no effect of Ruxo alone on mortality, but highlighted an increased risk of death in
patients who discontinued treatment.
In 162 of these patients (ET, n = 48), (PV, n = 42), (MF, n = 56), and (pre-PMF, n = 16), 15
major thromboses (3 arterial and 12 venous) were registered in 14 patients, of whom all, but
one, were receiving LMW-heparin prophylaxis. Independent risk factors for these events were
transfer to ICU (SHR = 3.73, p = 0.029), neutrophil/lymphocyte ratio (SHR = 1.1, p = 0.001) and
ET phenotype (SHR = 4.37, p = 0.006). The enhanced susceptibility to ET-associated VTE and
the associated higher mortality for pneumonia may recognize a common biological plausibility
and deserve to be delved to tailor new antithrombotic regimens including antiplatelet drugs.
SCIENTIFIC PROGRAMME
SESSION I
OPTIMIZING
CYTOREDUCTION
SESSION II
MANAGEMENT OF CML
WITH TKI
SESSION III
MPN RISK
STRATIFICATION
INCLUDING VASCULAR
EVENTS
DEBATE 1
INTERFERON ALPHA
SHOULD BE FRONT LINE
THERAPY IN ALL ET/PV
PATIENTS
ROUNDTABLE 1
INFECTIONS IN
MYELOPROLIFERATIVE
DISORDERS, INCLUDING
CML
ROUNDTABLE 2
PREGNANCY AND
PARENTING
DEBATE 2
ALLOGENEIC STEM CELL
TRANSPLANTATION
SHOULD BE CONSIDERED
THIRD LINE OPTION IN
CHRONIC PHASE CML
SESSION IV
EVOLVING THERAPIES
IN MYELOFIBROSIS
SESSION V
MANAGEMENT OF
ADVANCED AND UNUSUAL
DISEASE (MPN AND CML)
SESSION VI
TREATMENT FREE
REMISSION IN CML
KEYNOTE LECTURE
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FO R A POSTER
PRESENTATION
DISCLOSURES